NCT05829226
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05829226
Title A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors PureTech
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Cedars-Sinai Medical Center Los Angeles California 90048 United States Details
University of California Irvine Medical Center Orange California 92868 United States Details
Baptist Health South Florida-Miami Cancer Institute Miami Florida 02114 United States Details
Norton Healthcare-Norton Cancer Institute Louisville Kentucky 40207 United States Details
Mass. General Hospital-Harvard Boston Massachusetts 02114 United States Details
Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08901 United States Details
Rhode Island Hospital Providence Rhode Island 02903 United States Details
Virginia Commonwealth University Medical Center Richmond Virginia 23219 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field